US 9,980,994 B2Granted

Myxoma virus mutants for cancer treatment

AssigneeRobarts Research Institute

InventorsJohn W. Barrett, Grant McFadden

Life of this patent

Estimating the term…

Abstract

Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer.

Claims4

Dependent claims

A method for inhibiting a cancer cell comprising administering to the cell an effective amount of a Myxoma virus in which the gene for Myxoma virus protein M11L has been deleted or otherwise knocked-out.

Dependencies are inferred from the claim text.

Facts

Application: 15/002,971Filed 21 Jan 2016 · division
Priority: 1 Jun 2006
Published: US 2016/0136212 A119 May 2016
Granted: 29 May 2018
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61K 35/768
Viruses; Subviral particles; Bacteriophages: oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
A61K 35/76
Microorganisms or materials therefrom: viruses; Subviral particles; Bacteriophages
A61P 35/00
Antineoplastic agents
C12N 7/00
Viruses

Family

Application60/803,640Us provisional application · filed 1 Jun 2006
PCT/US2007/070219Parent of this continuation · filed 1 Jun 2007
Application13/969,853Parent of this division · filed 19 Aug 2013
US 8,512,713 B2Parent of this continuation · filed 20 Aug 2013
US 2016/0136212 A1Pre-grant publication · published 19 May 2016
Application12/301,961Parent of this continuation
Application13/969,853Parent of this continuation
US 2011/0158945 A1Published application
US 2013/0336930 A1Published application
US 9,980,994 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results